Significados de secondary measure em inglês

Analyses of a secondary measure of anhedonia found marginally significant effects in the same direction.

For each individual trial the main outcome measure was a symptom questionnaire; peak flow measurements were used as a secondary measure.

PMID: 1928975 For each individual trial the main outcome measure was a symptom questionnaire; peak flow measurements were used as a secondary measure.

Our secondary measure was percent of total available central processing unit (CPU) power used to access EHR servers at a given time.

Secondary measures included measures of verbal, nonverbal, memory, and executive functions.

Secondary measures of psychopathology, drug use, cognition and brain structure were also collected.

Significant differences favoring donepezil were noted at Week 24 LOCF for all secondary measures.

Donepezil also showed an improvement on the secondary measures.

Secondary measures included MRI utilization and imaging findings.

CCK-OP had no effect on other secondary measures and should not be recommended for the prevention of PNAC.

Secondary measures, while less unambiguous, were more in agreement with the P600-as-P3 hypothesis.

Significant improvements in key secondary measures (physical function, psoriasis) were evident with both apremilast doses versus placebo.

Botox patients also saw significant improvement on secondary measures, such as the frequency of urination and incontinence episodes, compared with the placebo patients.

There was also no difference between the 4 groups in secondary measures, with all groups showing a reduction in symptoms and increased functioning.

The primary efficacy endpoint was analyzed by using a mixed model for repeated measures; all secondary measures were analyzed by using an ANCOVA model.

Main outcome measures: The primary outcome measure was the Gross Motor Function Measure (GMFM-66); the secondary measures were problem score and energy cost.